

## **Illumina collaborates with National Cancer Center Japan**

25 January 2022 | News

### **Japan strengthens personalised cancer treatments for Nasopharyngeal Carcinoma**



Illumina, Inc. and the National Cancer Center Japan have announced an international joint research project that will use Illumina's high-throughput DNA sequencing to analyse the blood-based genomic profile and clinical information of patients living with Nasopharyngeal Carcinoma. The study will be known as a part of the Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN).

The A-TRAIN study led by the National Cancer Center Hospital Japan will be conducted as part of an international collaborative study under the Asian clinical Trials network for cAnceRS (ATLAS) project.

In this study, genomic analysis of blood samples of up to 96 patients with nasopharynx cancer will be analyzed using Illumina's TruSight™ Oncology 500 ctDNA.

Over the next year, the resulting data will be used by the Japan-led initiative to establish a platform for international collaborative trials with Malaysia, Thailand, the Philippines, Indonesia and Vietnam, which are actively promoting cancer treatment development in the Asian region.